Novavax Submits EUA Request for COVID-19 Vaccine Booster
The submission is supported by data from the phase 3 PREVENT-19 trial and the phase 2 COV-BOOST trial.
Vaccines
Poliovirus Discovered in NYC Wastewater
Discovery of poliovirus in sewage samples suggests there is already community transmission of the virus
MPR Weekly Dose Podcast #126
Emergency use authorization for intradermal administration of Jynneos; treatment approved for endometriosis pain; Amazon among the companies to receive a FDA Warning Letter for selling unapproved drugs; a diabetes drug is found to contain a possible carcinogen; and a new scale that measures peripheral impedance and pulse rate.
Most Older Americans Say They Will Get Updated COVID-19 Booster in Fall
Poll suggests ~61% of people over 50 who have gotten at least one dose of vaccine say they would get an updated booster
FDA Authorizes Intradermal Use of Jynneos to Increase Supply During Monkeypox Outbreak
Under the EUA, Jynneos can be administered either intradermally for individuals aged ≥18 years or subcutaneously for individuals aged <18 years.
Pfizer Testing Lyme Disease Vaccine Candidate in Phase 3 Trial
VLA15 is a 6-valent protein subunit vaccine that targets the outer surface protein A of Borrelia burgdorferi.
HPV Vaccination May Cut Risk for CIN2+ Recurrence
Effect estimate stronger for CIN2+ for disease related to HPV subtypes HPV 16 or HPV 18
Pneumococcal 24-Valent Conjugate Vaccine Gets Fast Track Designation
VAX-24 is an investigational 24-valent pneumococcal conjugate vaccine.
Vaccines for Monkeypox Prevention: Jynneos and ACAM2000
An individual is considered fully vaccinated about 2 weeks after the second dose of Jynneos and 4 weeks after receiving ACAM2000.
Simultaneous Flu Vaccine, COVID-19 Booster Safe
Systemic reactions generally mild, slightly more likely among those receiving both vaccines compared with COVID-19 mRNA booster alone
